US Federal Medical Device Procurement Teardown: Who Wins VA, DoD, and HHS Contracts
A data-driven analysis of $37.6B in federal medical device contracts. Learn which agencies buy, which suppliers win, and how to navigate VA, DoD, and HHS procurement channels.
Selling medical devices to the United States federal government represents one of the most lucrative yet structurally complex market-access pathways in the global healthcare industry. The federal government, operating through its major military, veterans, and civilian health agencies, acts as a massive institutional buyer. However, for business development (BD), market-access, and commercialization teams, the federal channel is frequently a black box. Traditional market intelligence often relies on qualitative descriptions of contracting vehicles or high-level budget allocations.
To provide commercial teams with decision-grade intelligence, this teardown analyzes 9,787 federal medical device contract records totaling $37.64 billion in obligated award dollars. This data, extracted from the primary federal spending registry (USAspending.gov), provides a complete picture of who actually captures federal device spending, how concentrated the recipient base is, and where realistic entry points exist for new or smaller medical device manufacturers.
By analyzing the data, we reveal that US federal medical-device procurement operates as a near-monopsony on the buyer side, dominated by three major agencies: the Department of Veterans Affairs (VA), the Department of Defense (DoD), and the Department of Health and Human Services (HHS). On the recipient side, the market is highly concentrated, distorted by pandemic-era diagnostics spending, locked up by broadline medical distributors, and anchored by a specialized hearing-aid oligopoly that feeds the VA's audiology channel.
Before committing commercial resources to federal bids, operators must understand this structural distribution of dollars, the multi-year vehicles that lock in incumbents, and the specific regulatory and commercial partnerships required to break into the channel.
Executive Summary: The Federal Procurement Landscape
For a high-level overview of the federal medical device purchasing landscape, the core data reveals a market characterized by heavy concentration and institutional procurement vehicles. The following table summarizes the key metrics from our teardown of the USAspending medical device contract database:
| Metric | Value | Breakdown / Notes |
|---|---|---|
| Total Tracked Contracts | 9,787 records | Cumulative award records including active and completed contracts. |
| Total Obligated Value | $37,638,513,903.00 | Obligated award dollars (realized funding commitments). |
| Top Three Agencies | 97.16% of total dollars | VA (47.08%), DoD (34.88%), HHS (15.20%). |
| Top Sub-Agencies | VA ($17.72B), DLA ($4.25B), Army ($6.07B) | Major buying commands that direct the actual purchasing. |
| Vehicle Concentration | 87.12% of total dollars | Delivery Orders under IDIQs (54.06%) + Definitive Contracts (33.06%). |
| COVID-Test Primes | $5.50B (14.62% of dollars) | Driven by Abbott Rapid DX ($3.37B) and iHealth Labs ($2.13B). |
| Broadline Distributors | $5.05B (13.43% of dollars) | Medline ($1.74B), Cardinal ($1.66B), McKesson ($699M), Concordance ($942M). |
| Hearing Aid Oligopoly | $2.83B (7.53% of dollars) | Sonova ($1.27B), Starkey ($565M), GN ($500M), Oticon ($498M). |
| Top Performance States | IL ($5.23B), FL ($4.83B), CA ($4.78B) | States where the contracted services or manufacturing occur. |
How is $37.6B in Federal Device Spend Split Across VA, DoD, and HHS?
The first structural reality of federal medical device procurement is the extreme concentration of purchasing authority. Of the $37.64 billion in obligated device contract dollars, 97.16% flows through just three departments:
- Department of Veterans Affairs (VA): Captures $17.72 billion (47.08% of total federal device spend) across 6,442 contracts.
- Department of Defense (DoD): Captures $13.13 billion (34.88% of total device spend) across 2,382 contracts.
- Department of Health and Human Services (HHS): Captures $5.71 billion (15.20% of total device spend) across 621 contracts.
The remaining 2.84% ($1.07 billion) is split among civilian agencies such as the Department of Justice (primarily the Federal Prison System, which registered 50 contracts totaling $63.79 million), the Department of Homeland Security (including the Transportation Security Administration, with 56 contracts totaling $59.04 million), and the General Services Administration (Federal Acquisition Service, with 44 contracts totaling $53.79 million).
The Institutional Sourcing Pipeline
The flow of federal device dollars can be conceptualized as a highly centralized funnel:
- The Buyer Pool ($37.64B): Split primarily between VA (47.1%), DoD (34.9%), and HHS (15.2%).
- Primary Sourcing Channels: Managed through the VA National Acquisition Center (NAC) for FSS and national contracts, the Defense Logistics Agency (DLA) Troop Support for military depots, and HHS ASPR for emergency stockpiles.
- Point-of-Care Delivery: Flowing to over 170 VA Medical Centers (VAMCs), hundreds of Military Treatment Facilities (MTFs) globally, Indian Health Service (IHS) clinics, and federal correctional facilities.
Which Sub-Agencies Actually Direct the Purchases?
Looking only at parent departments obscures where the actual buying decisions are made. Within the DoD and HHS, procurement authority is decentralized down to specific sub-agencies and commands. The table below lists the top 15 sub-agencies by contract count and dollar volume:
| Sub-Agency (Parent Department) | Contract Count | Obligated Dollars | Dollar Share (%) |
|---|---|---|---|
| Department of Veterans Affairs (VA) | 6,442 | $17,719,975,035.69 | 47.08% |
| Department of the Army (DoD) | 660 | $6,072,466,378.25 | 16.13% |
| Office of Assistant Secretary for Preparedness and Response (HHS/ASPR) | 103 | $4,446,430,198.44 | 11.81% |
| Defense Logistics Agency (DoD/DLA) | 1,068 | $4,248,199,879.55 | 11.29% |
| Department of the Air Force (DoD) | 132 | $1,226,909,641.23 | 3.26% |
| Department of the Navy (DoD) | 238 | $612,764,431.08 | 1.63% |
| Defense Contract Management Agency (DoD/DCMA) | 53 | $519,694,731.13 | 1.38% |
| Indian Health Service (HHS/IHS) | 287 | $375,222,819.83 | 1.00% |
| Defense Health Agency (DoD/DHA) | 184 | $363,029,806.98 | 0.96% |
| National Institutes of Health (HHS/NIH) | 123 | $242,809,370.21 | 0.65% |
| Office of the Assistant Secretary for Administration (HHS) | 62 | $74,143,256.73 | 0.20% |
| U.S. Special Operations Command (DoD/SOCOM) | 43 | $73,937,097.53 | 0.20% |
| Federal Prison System / Bureau of Prisons (DOJ) | 50 | $63,786,549.66 | 0.17% |
| Transportation Security Administration (DHS/TSA) | 56 | $59,042,105.52 | 0.16% |
| Federal Acquisition Service (GSA) | 44 | $53,787,792.92 | 0.14% |
Key Institutional Buying Patterns
To navigate this sub-agency landscape, commercial operators must understand three distinct purchasing patterns:
- The VA Hospital System: The VA operates as a single unified purchasing entity in this dataset. It represents the largest direct healthcare delivery network in the United States, running over 170 medical centers. Because it buys directly for its own clinical facilities, its contract count is high (6,442), reflecting thousands of individual local delivery orders and equipment purchases, alongside major national contracts managed by the VA National Acquisition Center (NAC).
- DoD Decentralization vs. DLA Aggregation: Within the military channel, DLA Troop Support (Medical Supply Chain) acts as the primary inventory manager, establishing major distribution agreements. However, the individual military branches—specifically the Army ($6.07 billion) and the Air Force ($1.23 billion)—retain substantial independent contracting authority. This is often used for combat-readiness equipment, field hospital deployments, and large-scale emergency defense contracts.
- ASPR and the Strategic National Stockpile: Within HHS, the Office of the Assistant Secretary for Preparedness and Response (ASPR) represents a massive outlier. With only 103 contract records, it has obligated $4.45 billion—an average of $43.17 million per contract. This is the agency responsible for the Strategic National Stockpile (SNS). Its purchases are characterized by high-volume, high-value, centralized procurements of ventilators, personal protective equipment (PPE), and diagnostic kits, which are stockpiled for national emergencies rather than distributed to local clinics.
For a broader conceptual framework of these purchasing channels, including GPOs, Federal Supply Schedules, and SAM.gov registration requirements, see our comprehensive federal procurement guide.
Which Companies Capture the Dollars: The Three Distortions
A naive analysis of the federal contractor list suggests that the market is open to all manufacturers. However, when we sum the obligated dollars by parent recipient entities, we find that the market is dominated by three specific categories of contractors, which we call the Three Distortions.
Together, these three distortions account for $13.39 billion, or 35.58% of the entire $37.64 billion federal device spending database, concentrated in just a few dozen companies.
Distortion 1: The COVID-19 Test Primes (14.62% of Spend)
The single largest dollar distortion in historical federal medical device contracting is the massive volume of emergency diagnostic contracts awarded during the pandemic. Two prime contractors alone capture $5.50 billion across just 101 contract records:
- Abbott Rapid DX North America LLC: Captured $3.37 billion across 97 contracts.
- iHealth Labs Inc.: Captured $2.13 billion across just 3 contracts (an average of $710.9 million per contract).
These awards were driven by ASPR and DoD (acting as the procurement agent for the federal government's nationwide free COVID-test distribution programs). For commercial teams evaluating the long-term federal market size for standard medical devices, these numbers must be stripped out. They represent emergency, non-recurring, pandemic-driven windfalls that do not reflect the baseline clinical procurement of the VA or military hospitals.
Distortion 2: Broadline Distributors (13.43% of Spend)
The second distortion is the prevalence of broadline medical distributors acting as the prime contractors of record. In many federal medical device database listings, the manufacturer's name does not appear. Instead, the contract is awarded to a distributor:
- Medline Industries, LP: 229 contracts, $1.74 billion obligated.
- Cardinal Health 200, LLC: 445 contracts, $1.66 billion obligated.
- Concordance Healthcare Solutions LLC: 57 contracts, $942.23 million obligated.
- McKesson Medical-Surgical Government Solutions LLC: 5 contracts, $699.39 million obligated.
This occurs because the DoD and VA utilize the Medical/Surgical Prime Vendor (MSPV) program. Under the MSPV model, the federal government selects a small number of broadline distributors to manage the logistics, warehousing, and delivery of medical supplies to individual VA clinics and military bases.
A manufacturer who wants to sell to the VA does not bid on a direct contract; instead, they must get their products "participating" on the MSPV catalog, and the hospital then orders the product through Medline or Cardinal. The distributor records the prime contract dollar obligated by the government, hiding the underlying manufacturer's revenue in the public database.
Distortion 3: The Hearing-Aid Oligopoly (7.53% of Spend)
The third distortion is a highly specialized clinical monopoly unique to the Department of Veterans Affairs. Audiology is one of the most heavily utilized services in the VA healthcare system, as hearing loss and tinnitus are the leading service-connected disabilities for veterans.
As a result, the VA acts as the largest single buyer of hearing aids in the world. Instead of purchasing from hundreds of local vendors, the VA National Acquisition Center awards national contracts to a consolidated "Big Four" hearing-aid oligopoly:
- Sonova USA Inc. (Phonak/Unitron): 76 contracts, $1.27 billion obligated.
- Starkey Laboratories Inc.: 108 contracts, $564.70 million obligated.
- GN Hearing Care Corporation (ReSound): 107 contracts, $500.08 million obligated.
- Oticon, Inc.: 109 contracts, $498.01 million obligated.
Combined, these four companies hold $2.83 billion in obligated contracts, representing 16.0% of all VA device spending. This oligopoly is highly stable; the contracts are multi-year national agreements, and the manufacturers ship products directly to VA audiology clinics nationwide. For any new entrant in the audiology or hearing health space, competing head-to-head with this established group at the national level is virtually impossible without an innovative, clinically differentiated device that can break into the VA National Contract schedule.
Detailed Breakdown: Top 20 Federal Medical Device Contractors
For competitive intelligence teams, the table below lists the top 20 federal medical device contractors by obligated dollars in our database. This list illustrates the mix of COVID test primes, broadline distributors, hearing aid manufacturers, and defense contractors:
| Rank | Contractor / Recipient Name | Contract Count | Obligated Dollars | Primary Channel / Classification |
|---|---|---|---|---|
| 1 | Abbott Rapid DX North America LLC | 97 | $3,368,652,944.96 | Diagnostic Primes (COVID-19 kits) |
| 2 | iHealth Labs Inc. | 3 | $2,132,749,987.20 | Diagnostic Primes (COVID-19 kits) |
| 3 | Medline Industries, LP | 229 | $1,735,528,674.43 | Broadline MSPV Distributor |
| 4 | Cardinal Health 200, LLC | 445 | $1,660,399,740.18 | Broadline MSPV Distributor |
| 5 | Sonova USA Inc. | 76 | $1,270,877,280.91 | VA Audiology Oligopoly |
| 6 | Concordance Healthcare Solutions LLC | 57 | $942,225,999.35 | Broadline MSPV Distributor |
| 7 | Olympus America Inc. | 501 | $801,969,748.55 | Surgical / Medical Endoscopy |
| 8 | Roche Diagnostics Corporation | 81 | $751,322,998.15 | In-Vitro Diagnostics / Reagents |
| 9 | McKesson Medical-Surgical Gov Solutions | 5 | $699,385,954.49 | Broadline MSPV Distributor |
| 10 | American Purchasing Services, LLC | 67 | $696,450,423.60 | Specialized Medical Distributor |
| 11 | Avon Protection Systems Incorporated | 115 | $643,198,460.54 | Defense / Respiratory Protection |
| 12 | Siemens Healthcare Diagnostics Inc. | 22 | $611,638,825.76 | In-Vitro Diagnostics / Clinical Lab |
| 13 | Medtronic Care Management Services, LLC | 132 | $607,961,506.60 | Electromedical / Remote Monitoring |
| 14 | First Nation Group LLC | 106 | $569,425,936.67 | SDVOSB Distributor (Respiratory/Sleep) |
| 15 | Starkey Laboratories Inc. | 108 | $564,696,430.81 | VA Audiology Oligopoly |
| 16 | Airboss Defense Group, LLC | 6 | $527,047,437.29 | Defense / Personal Protective Equipment |
| 17 | Medical Place Inc. | 69 | $521,358,571.62 | Specialized Medical Supplier |
| 18 | GN Hearing Care Corporation | 107 | $500,078,868.74 | VA Audiology Oligopoly |
| 19 | Oticon, Inc. | 109 | $498,012,421.83 | VA Audiology Oligopoly |
| 20 | Kreisers, LLC | 57 | $490,253,023.16 | Regional Medical Distributor |
Why Do 87% of Dollars Flow Through IDIQ/FSS/BPA Vehicles?
For a medical device company used to commercial sales (where a hospital purchasing agent signs a purchase order for a batch of products), the federal procurement process can be baffling. The primary reason is that the government is legally barred from buying products on an ad-hoc basis if a structured contract vehicle exists.
In our teardown, we analyzed the award types across the 9,787 contract records. The data shows that the vast majority of federal device dollars are obligated through multi-year, pre-negotiated contract vehicles rather than one-off transactions:
- Delivery Orders (54.06% / $20.35 billion): These are individual orders placed against an existing Indefinite Delivery, Indefinite Quantity (IDIQ) contract, such as the VA Federal Supply Schedule (FSS) or the DLA Defense Biologics/Medical contracts. The pricing, terms, and regulatory compliance (such as Trade Agreements Act compliance) are negotiated once when the IDIQ is established. Individual VA or military hospitals then issue "Delivery Orders" to buy specific quantities of devices under those terms.
- Definitive Contracts (33.06% / $12.44 billion): These are large, standalone contracts awarded for a specific, defined project or long-term procurement (e.g., the massive national stockpile acquisitions managed by ASPR or military combat-readiness programs). They require a full, open competitive bidding process under the Federal Acquisition Regulation (FAR).
- Purchase Orders (7.38% / $2.78 billion): These are one-off, direct commercial-style purchases. They are typically used for low-value purchases (below the Simplified Acquisition Threshold, which is generally $250,000) or when an individual clinical facility has an urgent, non-recurring need for a specific device that is not available on any active FSS or MSPV catalog.
- Blanket Purchase Agreement (BPA) Calls (3.27% / $1.23 billion): These are calls placed against a pre-established BPA. BPAs are simplified methods of filling recurring needs for supplies or services by establishing "charge accounts" with qualified sources.
The Strategic Lesson for Manufacturers
If you are a medical device manufacturer attempting to sell to the federal government, chasing individual solicitations on SAM.gov is a low-probability, high-cost strategy. Because 87.12% of all device dollars flow through Delivery Orders and Definitive Contracts, your primary objective must be to get your products listed on an approved contract vehicle.
If your device is not on the VA FSS, the GSA Schedule, or a DLA DAPA agreement, a clinical champion at a VA hospital cannot buy your product, even if they prefer it clinically. They are legally bound by "Required Sources of Supply" rules (FAR Part 8) to buy from established schedules first.
To compare this centralized public-sector purchasing model with other global single-buyer systems, such as Saudi Arabia's NUPCO tender program, see our analysis of the Saudi NUPCO device procurement model.
Where Are the Realistic Entry Lanes for New Entrants?
Given the concentration of dollars in distributors, COVID-test giants, and hearing aid manufacturers, how can a new or mid-sized medical device manufacturer successfully enter the US federal channel? There are four realistic lanes:
Lane 1: Partnering with an SDVOSB (The VA "Rule of Two")
For civilian medical devices, the Department of Veterans Affairs is the primary target. However, the VA is bound by the Veterans Benefits, Health Care, and Information Technology Act of 2006, which mandates the "Rule of Two." This rule requires the VA to set aside contracting opportunities for Service-Disabled Veteran-Owned Small Businesses (SDVOSBs) or Veteran-Owned Small Businesses (VOSBs) before opening a competition to large prime manufacturers, provided there is a reasonable expectation that at least two such businesses will submit competitive offers at a fair price.
Because most medical device manufacturers are not veteran-owned, the most effective entry lane is to partner with an established SDVOSB distributor (such as First Nation Group, Lovell Government Services, or Spartan Medical). In this model, the manufacturer sells the device to the SDVOSB partner, who holds the prime FSS contract and manages the federal sales and distribution.
In our dataset, First Nation Group LLC alone holds 106 contracts representing $569.43 million in obligated dollars, primarily by acting as the SDVOSB distributor of record for respiratory and sleep-therapy devices (such as CPAP machines and ventilators) manufactured by large multinational firms.
Lane 2: DLA Distribution and Pricing Agreements (DAPA)
For military medical procurement, the entry point is the Defense Logistics Agency (DLA) Troop Support. To sell devices to military treatment facilities (MTFs), a manufacturer must secure a Distribution and Pricing Agreement (DAPA). A DAPA is not a contract that guarantees sales; rather, it is a pricing agreement that establishes the maximum price the military will pay for your products.
Once a DAPA is active, your products can be added to the DLA's Medical/Surgical Prime Vendor (MSPV) catalog. The physical logistics and delivery are then handled by the DLA's prime vendors (such as Cardinal Health or Owens & Minor), but the clinical demand is generated by the MTFs ordering your product from the catalog.
Lane 3: Secured Placement on GSA / VA Federal Supply Schedules
Securing a spot on the VA Federal Supply Schedule (FSS)—specifically Schedule 65 II A (Medical Equipment and Supplies) or Schedule 65 I B (Pharmaceuticals and Medical Solutions)—is the standard civilian entry point. The FSS is a rolling solicitation, meaning a manufacturer can submit a proposal at any time. The process requires a detailed audit of the manufacturer's commercial sales practices to ensure the government receives the "Most Favored Customer" pricing.
Securement of an FSS contract provides a pre-negotiated contract vehicle that any federal agency (including the Indian Health Service, Bureau of Prisons, and DoD) can use to buy your devices.
Lane 4: Direct Sub-Agency Targeting (Civilian & Defense)
If the barriers to entry at the national VA or DLA level are too high, smaller manufacturers should target sub-agencies that have distinct clinical needs and lower contract concentration. For example, the Indian Health Service (IHS) represents 287 contracts and $375.22 million in device spending. The IHS operates hospitals and clinics in remote areas, often serving Native American and Alaska Native populations.
Similarly, the Defense Health Agency (DHA) directs 184 contracts totaling $363.03 million, focusing on integrating clinical care across the military branches. These agencies frequently buy specialized diagnostic, patient monitoring, and point-of-care devices through simplified acquisition procedures or small-business set-asides that bypass the massive prime vendor distributors.
To understand how US federal procurement concentration compares with European public healthcare procurement, see our analysis of EU TED medical device tenders.
The Trade Agreements Act (TAA) Barrier in Federal Procurement
A critical regulatory hurdle that catches many foreign and domestic device manufacturers off guard is the Trade Agreements Act of 1979 (TAA) (19 U.S.C. § 2501 et seq.).
Under FAR subpart 25.4, any product acquired through a federal contract valued above a certain threshold (typically $183,000 for supply contracts, though it fluctuates) must be a "domestic end product" or a "designated country end product."
TAA Compliance Requirements
- TAA Designated Countries: Include countries with which the US has free trade agreements (e.g., Canada, Mexico, Australia, Germany, Japan, South Korea, Singapore).
- Non-Designated Countries: Crucially, China, India, Brazil, Malaysia, and Thailand are NOT TAA-designated countries.
- The Sourcing Impact: If your medical device is manufactured or undergoes its "substantial transformation" in China or India, it is legally barred from being listed on the VA FSS or GSA Schedule.
- Exception Processes: Bypassing TAA rules requires proving to the contracting officer that there are no TAA-compliant alternatives available on the market (a "non-availability determination"), which is extremely difficult to obtain for standard class II devices.
Therefore, prior to bidding on any federal contract or partnering with an SDVOSB distributor, manufacturers must audit their supply chain. If assembly occurs in a non-designated country, the firm must relocate final assembly or "substantial transformation" to a TAA-compliant country, or risk immediate disqualification.
Step-by-Step Registration and Compliance Workflow
For a new entrant, the pathway to winning federal device contracts follows a strict sequence of compliance gates. Bypassing any step will stall progress.
Step 1: Obtain a Unique Entity ID (UEI) via SAM.gov
│
▼
Step 2: Secure a Commercial and Government Entity (CAGE) Code
│
▼
Step 3: Audit Supply Chain for TAA (Trade Agreements Act) Compliance
│
▼
Step 4: Establish VA FSS Schedule 65 II A Pricing (or DAPA Agreement)
│
▼
Step 5: Identify and Partner with a Verified SDVOSB Distributor
│
▼
Step 6: Register Products on the VA/DLA MSPV Catalog
│
▼
Step 7: Target Individual Hospital Clinicians to Drive Catalog Pull-Through
1. SAM.gov and UEI Registration
Every federal contractor must register in the System for Award Management (SAM.gov). Upon registration, you are issued a Unique Entity ID (UEI) (which replaced the legacy DUNS number). The registration is free but requires verifying your corporate tax ID, banking details for direct payment, and executive compensation disclosures.
2. CAGE Code Acquisition
During SAM registration, US-based firms are assigned a five-character CAGE (Commercial and Government Entity) Code by the Defense Logistics Agency. This code acts as your unique identifier for security clearances, shipping, and payments.
3. FSS Pricing Negotiation (VA NAC)
For civilian sales, submit a proposal for VA Schedule 65 II A. You must disclose your commercial sales practices, identifying your "Most Favored Customer" (MFC). The VA will negotiate a discount that ensures the government receives a price equal to or better than your MFC price.
4. SDVOSB Partnership
To accelerate VA sales, execute a distribution agreement with a verified SDVOSB. Ensure the partner is listed in the SBA's VetBiz database (now managed by the SBA under the VetCert program). The SDVOSB partner will add your products to their existing FSS contract as a modification, bypassing the 12-month wait time for a new contract award.
The Geography of Federal Device Spend: Where the Dollars Land
An analysis of the place of performance (the state where the contracted work is performed, the products are distributed, or the services are rendered) reveals that federal device spending is highly concentrated in a few key geographic corridors. The top 5 states by obligated dollars represent $21.17 billion, or 56.24% of all tracked spending:
- Illinois (IL): 886 contracts, $5.23 billion (13.89% of spend).
- Florida (FL): 674 contracts, $4.83 billion (12.83% of spend).
- California (CA): 976 contracts, $4.78 billion (12.71% of spend).
- Georgia (GA): 211 contracts, $2.29 billion (6.10% of spend).
- Pennsylvania (PA): 607 contracts, $2.04 billion (5.42% of spend).
Why do these states dominate?
- Illinois acts as the primary distribution hub for several major medical manufacturers and is home to the corporate headquarters of Abbott Laboratories (driving the $3.37 billion Abbott Rapid DX contract performance listing in the state).
- Florida is a critical logistics corridor and represents the place of performance for major national distribution contracts and emergency preparedness stockpiles.
- California represents the primary manufacturing and engineering cluster for electromedical, diagnostic, and surgical systems.
This geographic corridor (specifically California and Pennsylvania) overlaps significantly with the states that dominate federal R&D funding and public-company registrations. For example, California and Massachusetts are the undisputed leaders in securing NIH SBIR medical device grants.
This indicates that the federal government is not only a major buyer of finished clinical devices, but also a critical funder of the early-stage engineering that feeds the public medtech pipeline.
Data Limitations and Methodological Constraints
When using federal procurement data for commercial strategic planning, teams must acknowledge several inherent limitations in the USAspending database:
- Obligated vs. Realized Spend: The dollar figures in this teardown represent obligated contract actions. An obligation is a legal commitment by the government to pay for goods or services. It does not always map 1:1 with actual outlays (cash paid). For large IDIQ contracts, the government may obligate a massive ceiling amount that is not fully drawn down by individual hospitals.
- Empty Fiscal Year Fields: In this specific USAspending extract, the
fiscal_yearsfield was empty across all 9,787 rows. As a result, we cannot construct a year-over-year time-series trend of procurement growth or separate pre-pandemic baselines from post-pandemic realities using this column. The totals represent a cumulative, multi-year historical snapshot. - Lack of Set-Aside Fields: The raw dataset does not contain columns identifying small-business, veteran-owned, or SDVOSB set-aside status. These designations must be inferred by cross-referencing recipient names with the Small Business Administration (SBA) or VA VetBiz registries.
- Distributor Masking: As detailed in the "Distributor Distortion" section, the use of Prime Vendor models (MSPV) means that hundreds of millions of dollars in device spending are credited to Medline or Cardinal Health, masking the true market-share capture of individual device manufacturers.
FAQ: Frequently Asked Questions
What share of US federal medical-device contract dollars does the VA capture?
The Department of Veterans Affairs (VA) is the single largest buyer in the federal medical device database. It captures 47.08% of all obligated device contract dollars, totaling $17.72 billion across 6,442 contracts. This reflects the VA's role as the operator of the nation's largest integrated healthcare network.
Do I have to be a prime contractor to sell devices to the federal government?
No. In fact, for most small-to-mid-sized manufacturers, acting as a prime contractor is highly inefficient.
Instead, companies typically sell through established prime contractors, such as broadline distributors (Medline, Cardinal) who manage the VA/DoD MSPV catalogs, or through Service-Disabled Veteran-Owned Small Business (SDVOSB) partners who hold specialized set-aside contracts with the VA.
How distorted is the data by COVID-era test procurement?
The data is heavily distorted by emergency diagnostic contracting. Two companies—Abbott Rapid DX North America and iHealth Labs—account for $5.50 billion, or 14.62% of all tracked device contract dollars. When sizing the recurring, baseline clinical opportunity for medical hardware or implants, these emergency test kit acquisitions should be excluded from the analysis.
Which federal sub-agencies are realistic targets for a smaller device manufacturer?
Smaller manufacturers should target the Indian Health Service (IHS), which holds 287 contracts totaling $375.22 million, and the Defense Health Agency (DHA), with 184 contracts totaling $363.03 million.
These agencies often buy specialized point-of-care, diagnostic, and monitoring equipment, and their procurement structures are frequently more accessible than the massive, consolidated prime-vendor systems managed by the VA and DLA.
Conclusion: Strategic Recommendations for Medtech Operators
The federal medical device procurement database reveals a highly concentrated, vehicle-driven market. To capture federal dollars, commercial teams must pivot away from local commercial sales tactics and adopt a structured, channel-specific strategy:
- Strip Out the Windfalls: When calculating your Total Addressable Market (TAM) in the federal space, subtract the COVID-test primes ($5.50B) and the hearing-aid national contracts ($2.83B) to find the realistic baseline clinical spend for your product class.
- Prioritize the Vehicle Over the Customer: Do not spend time marketing to VA clinicians until you have secured a contract vehicle (VA FSS DAPA or an SDVOSB distribution partner). Without a vehicle, a clinician has no regulatory mechanism to purchase your device.
- Partner for the VA, Price for the DoD: If targeting the VA, identify a qualified SDVOSB partner to leverage the "Rule of Two" set-asides. If targeting the military channel (DoD/MTFs), focus on securing a DAPA agreement with the DLA to lock in your pricing and gain entry to the MSPV logistics pipeline.
- Enforce Supply-Chain TAA Compliance: Before committing to a federal channel strategy, review all manufacturing bills of materials. If your products are assembled in non-designated countries (such as China or India), you must reorganize assembly processes to TAA-compliant countries to avoid legal disqualification.
By treating federal procurement as a structured market-access exercise rather than a standard sales cycle, device manufacturers can secure stable, multi-year revenue streams backed by the credit of the US government.
Disclaimer: The analysis presented in this article is based on historical contract data from USAspending.gov and official program policies. It is intended for educational and strategic planning purposes only and does not constitute legal, regulatory, or government contracting advice. Manufacturers should consult qualified federal contracting counsel before submitting proposals.